Spelling suggestions: "subject:"clonidine""
1 |
IMIDAZOLINE RECEPTORS IN INSULIN SIGNALING AND METABOLIC REGULATIONSun, Zheng January 2007 (has links)
No description available.
|
2 |
Le contrôle de l'hypertrophie cardiaque par la moxonidinePaquette, Pierre-Alexandre January 2007 (has links)
Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal.
|
3 |
Le contrôle de l'hypertrophie cardiaque par la moxonidinePaquette, Pierre-Alexandre January 2007 (has links)
Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal
|
4 |
Les récepteurs aux imidazolines dans le coeur : identification, distribution et fonctionEl-Ayoubi, Rouwayda January 2005 (has links)
Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.
|
5 |
Efeito da ketamina sobre a hipotensão induzida pelo choque endotoxêmico: participação do óxido nítrico e vasopressina / Effect of ketamine on the hypotension induced endotoxemic shock: role of nitric oxide and vasopressinRossin, Patrícia Renata 08 October 2013 (has links)
A fisiopatologia do choque séptico caracteriza-se por uma produção excessiva de mediadores inflamatórios, dentre eles o óxido nítrico (NO), conduzindo a uma hipotensão prolongada associada a um aumento inicial de vasopressina (AVP) e uma diminuição na fase tardia. A ketamina é um anestésico com propriedades cardioestimulatórias e anti-inflamatórias. O presente trabalho testou a hipótese de que a ketamina, através de suas propriedades anti-inflamatórias no choque séptico, teria uma ação inibitória sobre a síntese do óxido nítrico, favorecendo a liberação de AVP e preservando a função cardiovascular. O choque endotoxêmico foi induzido através de uma injeção i.v. de 1,5 mg/kg de lipopolissacarídeo (LPS) em ratos Wistar adultos machos. Após a injeção de LPS, um grupo de animais foi tratado com ketamina (10 mg/kg) e o grupo controle recebeu salina. A administração de LPS produziu uma queda significativa da pressão arterial média (PAM) (p<0,01) associada a um aumento da freqüência cardíaca (FC) (p<0,01). Essas alterações foram acompanhadas por uma elevação significativa nas concentrações plasmáticas de AVP após duas horas (p<0,01), seguida de queda nas próximas horas, e por uma elevação nas concentrações de NO plasmático (p<0,01). Quando o LPS foi combinado à administração i.v. de ketamina, observou-se uma atenuação da hipotensão (p<0,01) e uma potencialização na liberação de AVP (p<0,01) pelo LPS. No entanto, a produção de NO após a adminstração da ketamina não mostrou diferença em relação ao LPS, indicando não ser esta a via utilizada pela ketamina. Para verificar o papel da ativação simpática na preservação da função cardiovascular pela ketamina no choque endotoxêmico, utilizou-se um inibidor simpático central, a moxonidina (MOXO). O pré-tratamento i.v. com MOXO (50 µg /Kg) atenuou significativamente o aumento da FC produzido pela ketamina (p < 0,05) apenas na segunda e quarta horas, porém com ação não significativa sobre a PAM. Estes dados sugerem um efeito cardioestimulatório da ketamina no choque séptico principalmente por uma potencialização na liberação da AVP e esta parece não se dar pela via do NO / The pathophysiology of septic shock is characterized by excessive production of inflammatory mediators, including nitric oxide (NO), leading to a prolonged hypotension associated with an initial increase of vasopressin (AVP) and a late phase decrease. Ketamine is an anesthetic with cardiostimulatory and anti- inflammatory properties. The present study tested the hypothesis that ketamine, through its anti-inflammatory properties in septic shock, have an inhibitory effect on the synthesis of nitric oxide, promoting the release of AVP and preserving cardiovascular function. Endotoxemic shock was induced by an iv injection of 1.5 mg / kg lipopolysaccharide (LPS) in adult male Wistar rats. After LPS injection, a group of animals was treated with ketamine (10 mg / kg) and the control group received saline. The LPS administration produced a significant decrease in mean arterial pressure (MAP) (p <0.01) associated with an increase in heart rate (HR) (p <0,01). These changes were accompanied by significant increases in plasma AVP after two hours (p <0.01), followed by fall in the coming hours, and plasma NO increasing (p <0.01). When LPS was combined with iv ketamine administration, there was an attenuation of hypotension (p <0.01) and an enhancement in the release of AVP (p <0.01) by LPS. However, the production of NO after ketamine adminstration showed no difference compared to LPS, indicating this is not the route used by ketamine. To verify the role of sympathetic activation in ketamine\'s preservation of cardiovascular function in endotoxemic shock, used a central sympathetic inhibitor, moxonidine (moxo). Pretreatment with moxo iv (50 µg / kg) significantly attenuated the increase in HR produced by ketamine (p <0.05) only in the second and fourth hour, but with no significant action on the MAP. These data suggest that the cardiostimulatory effect of ketamine in septic shock primarily occurs by potentiation of AVP release, and this does not seem to give the NO pathway
|
6 |
Efeito da ketamina sobre a hipotensão induzida pelo choque endotoxêmico: participação do óxido nítrico e vasopressina / Effect of ketamine on the hypotension induced endotoxemic shock: role of nitric oxide and vasopressinPatrícia Renata Rossin 08 October 2013 (has links)
A fisiopatologia do choque séptico caracteriza-se por uma produção excessiva de mediadores inflamatórios, dentre eles o óxido nítrico (NO), conduzindo a uma hipotensão prolongada associada a um aumento inicial de vasopressina (AVP) e uma diminuição na fase tardia. A ketamina é um anestésico com propriedades cardioestimulatórias e anti-inflamatórias. O presente trabalho testou a hipótese de que a ketamina, através de suas propriedades anti-inflamatórias no choque séptico, teria uma ação inibitória sobre a síntese do óxido nítrico, favorecendo a liberação de AVP e preservando a função cardiovascular. O choque endotoxêmico foi induzido através de uma injeção i.v. de 1,5 mg/kg de lipopolissacarídeo (LPS) em ratos Wistar adultos machos. Após a injeção de LPS, um grupo de animais foi tratado com ketamina (10 mg/kg) e o grupo controle recebeu salina. A administração de LPS produziu uma queda significativa da pressão arterial média (PAM) (p<0,01) associada a um aumento da freqüência cardíaca (FC) (p<0,01). Essas alterações foram acompanhadas por uma elevação significativa nas concentrações plasmáticas de AVP após duas horas (p<0,01), seguida de queda nas próximas horas, e por uma elevação nas concentrações de NO plasmático (p<0,01). Quando o LPS foi combinado à administração i.v. de ketamina, observou-se uma atenuação da hipotensão (p<0,01) e uma potencialização na liberação de AVP (p<0,01) pelo LPS. No entanto, a produção de NO após a adminstração da ketamina não mostrou diferença em relação ao LPS, indicando não ser esta a via utilizada pela ketamina. Para verificar o papel da ativação simpática na preservação da função cardiovascular pela ketamina no choque endotoxêmico, utilizou-se um inibidor simpático central, a moxonidina (MOXO). O pré-tratamento i.v. com MOXO (50 µg /Kg) atenuou significativamente o aumento da FC produzido pela ketamina (p < 0,05) apenas na segunda e quarta horas, porém com ação não significativa sobre a PAM. Estes dados sugerem um efeito cardioestimulatório da ketamina no choque séptico principalmente por uma potencialização na liberação da AVP e esta parece não se dar pela via do NO / The pathophysiology of septic shock is characterized by excessive production of inflammatory mediators, including nitric oxide (NO), leading to a prolonged hypotension associated with an initial increase of vasopressin (AVP) and a late phase decrease. Ketamine is an anesthetic with cardiostimulatory and anti- inflammatory properties. The present study tested the hypothesis that ketamine, through its anti-inflammatory properties in septic shock, have an inhibitory effect on the synthesis of nitric oxide, promoting the release of AVP and preserving cardiovascular function. Endotoxemic shock was induced by an iv injection of 1.5 mg / kg lipopolysaccharide (LPS) in adult male Wistar rats. After LPS injection, a group of animals was treated with ketamine (10 mg / kg) and the control group received saline. The LPS administration produced a significant decrease in mean arterial pressure (MAP) (p <0.01) associated with an increase in heart rate (HR) (p <0,01). These changes were accompanied by significant increases in plasma AVP after two hours (p <0.01), followed by fall in the coming hours, and plasma NO increasing (p <0.01). When LPS was combined with iv ketamine administration, there was an attenuation of hypotension (p <0.01) and an enhancement in the release of AVP (p <0.01) by LPS. However, the production of NO after ketamine adminstration showed no difference compared to LPS, indicating this is not the route used by ketamine. To verify the role of sympathetic activation in ketamine\'s preservation of cardiovascular function in endotoxemic shock, used a central sympathetic inhibitor, moxonidine (moxo). Pretreatment with moxo iv (50 µg / kg) significantly attenuated the increase in HR produced by ketamine (p <0.05) only in the second and fourth hour, but with no significant action on the MAP. These data suggest that the cardiostimulatory effect of ketamine in septic shock primarily occurs by potentiation of AVP release, and this does not seem to give the NO pathway
|
7 |
L’amélioration de la performance et de la structure cardiaque par la moxonidine chez les SHR est accompagnée d’une diminution des cytokines, de la MAPK p38 et de l’AktFarah, Georges 12 1900 (has links)
L’hypertrophie du ventricule gauche (HVG) est un processus adaptif et compensatoire qui se développe conséquemment à l’hypertension artérielle pour s’opposer à l’élévation chronique de la pression artérielle. L’HVG est caractérisée par une hypertrophie des cardiomyocytes suite à l’augmentation de la synthèse d’ADN, une prolifération des fibroblastes, une augmentation du dépôt de collagène et une altération de la matrice extracellulaire (MEC). Ces changements génèrent des troubles de relaxation et mènent au dysfonctionnement diastolique, ce qui diminue la performance cardiaque. La suractivité du système nerveux sympathique (SNS) joue un rôle essentiel dans le développement de l’hypertension artérielle et de l’HVG à cause de la libération excessive des catécholamines et de leurs effets sur la sécrétion des cytokines pro-inflammatoires et sur les différentes voies de signalisation hypertrophiques et prolifératives. Le traitement antihypertenseur avec de la moxonidine, un composé sympatholytique d’action centrale, permet une régression de l’HVG suite à une réduction soutenue de la synthèse d'ADN et d’une stimulation transitoire de la fragmentation de l'ADN qui se produit au début du traitement. En raison de l’interaction entre l’HVG, les cytokines inflammatoires, le SNS et leurs effets sur les protéines de signalisation hypertrophiques, l’objectif de cette étude est de détecter dans un modèle animal d’hypertension artérielle et d’HVG, les différentes voies de signalisation associées à la régression de l’HVG et à la performance cardiaque. Des rats spontanément hypertendus (SHR, 12 semaines) ont reçu de la moxonidine à 0, 100 et 400 µg/kg/h, pour une période de 1 et 4 semaines, via des mini-pompes osmotiques implantées d’une façon sous-cutanée. Après 4 semaines de traitement, la performance cardiaque a été mesurée par écho-doppler. Les rats ont ensuite été euthanasiés, le sang a été recueilli pour mesurer les concentrations des cytokines plasmatiques et les cœurs ont été prélevés pour la détermination histologique du dépôt de collagène et de l'expression des protéines de signalisation dans le ventricule gauche. Le traitement de 4 semaines n’a eu aucun effet sur les paramètres systoliques mais a permis d’améliorer les paramètres diastoliques ainsi que la performance cardiaque globale. Par rapport au véhicule, la moxonidine (400 µg/kg/h) a permis d’augmenter transitoirement la concentration plasmatique de l’IL-1β après une semaine et de réduire la masse ventriculaire gauche. De même, on a observé une diminution du dépôt de collagène et des concentrations plasmatiques des cytokines IL-6 et TNF-α, ainsi qu’une diminution de la phosphorylation de p38 et d’Akt dans le ventricule gauche après 1 et 4 semaines de traitement, et cela avec une réduction de la pression artérielle et de la fréquence cardiaque. Fait intéressant, les effets anti-hypertrophiques, anti-fibrotiques et anti-inflammatoires de la moxonidine ont pu être observés avec la dose sous-hypotensive (100 µg/kg/h). Ces résultats suggèrent des effets cardiovasculaires bénéfiques de la moxonidine associés à une amélioration de la performance cardiaque, une régulation de l'inflammation en diminuant les niveaux plasmatiques des cytokines pro-inflammatoires ainsi qu’en inhibant la MAPK p38 et Akt, et nous permettent de suggérer que, outre l'inhibition du SNS, moxonidine peut agir sur des sites périphériques. / Left ventricular hypertrophy (LVH) is an adaptive and compensatory process that develops in hypertension to oppose the chronic elevation of blood pressure. LVH is characterized by hypertrophy of cardiomyocytes following the increase in DNA synthesis, proliferation of fibroblasts, increased collagen deposition and alteration of the extracellular matrix (ECM). These changes generate relaxation and diastolic dysfunction which reduced cardiac performance. The overactivity of the sympathetic nervous system plays an essential role in the development of hypertension and left ventricular hypertrophy pathogenesis due to the excessive release of catecholamines and norepinephrine spillover and their effects on the secretion of pro-inflammatory cytokines and hypertrophic signaling pathways. Antihypertensive treatment with moxonidine, a centrally acting sympatholytic imidazoline compound, results in prevention of left ventricular hypertrophy, resulting from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation that occur early after treatment. Due to the interaction between LVH, inflammatory cytokines, the SNS and their effects on hypertrophic signaling proteins, the objective of this study is to detect in an animal model of hypertension and LVH, the different signaling pathways associated with regression of LVH and cardiac performance. Spontaneously hypertensive rats (SHR, 12 weeks old) received moxonidine at 0, 100 and 400 µg/kg/h, for 1 and 4 weeks, via subcutaneously implanted osmotic minipumps. After 4 weeks of treatment, cardiac performance was measured by echo-Doppler. Then the rats were euthanized, blood was collected for measurement of plasma cytokines and hearts for histologic determination of collagen deposition and for measurement of left ventricular expression of downstream signaling proteins. Treatment for 4 weeks had no effect on systolic parameters but improved diastolic parameters and global cardiac performance. Compared to vehicle, moxonidine (400 µg/kg/h) transiently increased plasma IL-1β after 1 week and reduced left ventricular mass. Similarly, there was a decrease in collagen deposition and plasma concentrations of IL-6 and TNF-α, and decreased phosphorylation of p38 and Akt in the left ventricle after 1 and 4 weeks treatment, in association with reduced blood pressure and heart rate. Interestingly, the anti-hypertrophic, anti-fibrotic, and anti-inflammatory effects of moxonidine were observed with a sub-hypotensive dose (100µg/kg/h). These results suggest the beneficial cardiovascular effects of moxonidine associated with improved cardiac performance, regulation of inflammation by decreasing pro-inflammatory plasma levels, inhibition of p38 MAPK and Akt, and allow us to suggest that besides inhibiting the SNS, moxonidine may act on peripheral sites.
|
8 |
L’amélioration de la performance et de la structure cardiaque par la moxonidine chez les SHR est accompagnée d’une diminution des cytokines, de la MAPK p38 et de l’AktFarah, Georges 12 1900 (has links)
L’hypertrophie du ventricule gauche (HVG) est un processus adaptif et compensatoire qui se développe conséquemment à l’hypertension artérielle pour s’opposer à l’élévation chronique de la pression artérielle. L’HVG est caractérisée par une hypertrophie des cardiomyocytes suite à l’augmentation de la synthèse d’ADN, une prolifération des fibroblastes, une augmentation du dépôt de collagène et une altération de la matrice extracellulaire (MEC). Ces changements génèrent des troubles de relaxation et mènent au dysfonctionnement diastolique, ce qui diminue la performance cardiaque. La suractivité du système nerveux sympathique (SNS) joue un rôle essentiel dans le développement de l’hypertension artérielle et de l’HVG à cause de la libération excessive des catécholamines et de leurs effets sur la sécrétion des cytokines pro-inflammatoires et sur les différentes voies de signalisation hypertrophiques et prolifératives. Le traitement antihypertenseur avec de la moxonidine, un composé sympatholytique d’action centrale, permet une régression de l’HVG suite à une réduction soutenue de la synthèse d'ADN et d’une stimulation transitoire de la fragmentation de l'ADN qui se produit au début du traitement. En raison de l’interaction entre l’HVG, les cytokines inflammatoires, le SNS et leurs effets sur les protéines de signalisation hypertrophiques, l’objectif de cette étude est de détecter dans un modèle animal d’hypertension artérielle et d’HVG, les différentes voies de signalisation associées à la régression de l’HVG et à la performance cardiaque. Des rats spontanément hypertendus (SHR, 12 semaines) ont reçu de la moxonidine à 0, 100 et 400 µg/kg/h, pour une période de 1 et 4 semaines, via des mini-pompes osmotiques implantées d’une façon sous-cutanée. Après 4 semaines de traitement, la performance cardiaque a été mesurée par écho-doppler. Les rats ont ensuite été euthanasiés, le sang a été recueilli pour mesurer les concentrations des cytokines plasmatiques et les cœurs ont été prélevés pour la détermination histologique du dépôt de collagène et de l'expression des protéines de signalisation dans le ventricule gauche. Le traitement de 4 semaines n’a eu aucun effet sur les paramètres systoliques mais a permis d’améliorer les paramètres diastoliques ainsi que la performance cardiaque globale. Par rapport au véhicule, la moxonidine (400 µg/kg/h) a permis d’augmenter transitoirement la concentration plasmatique de l’IL-1β après une semaine et de réduire la masse ventriculaire gauche. De même, on a observé une diminution du dépôt de collagène et des concentrations plasmatiques des cytokines IL-6 et TNF-α, ainsi qu’une diminution de la phosphorylation de p38 et d’Akt dans le ventricule gauche après 1 et 4 semaines de traitement, et cela avec une réduction de la pression artérielle et de la fréquence cardiaque. Fait intéressant, les effets anti-hypertrophiques, anti-fibrotiques et anti-inflammatoires de la moxonidine ont pu être observés avec la dose sous-hypotensive (100 µg/kg/h). Ces résultats suggèrent des effets cardiovasculaires bénéfiques de la moxonidine associés à une amélioration de la performance cardiaque, une régulation de l'inflammation en diminuant les niveaux plasmatiques des cytokines pro-inflammatoires ainsi qu’en inhibant la MAPK p38 et Akt, et nous permettent de suggérer que, outre l'inhibition du SNS, moxonidine peut agir sur des sites périphériques. / Left ventricular hypertrophy (LVH) is an adaptive and compensatory process that develops in hypertension to oppose the chronic elevation of blood pressure. LVH is characterized by hypertrophy of cardiomyocytes following the increase in DNA synthesis, proliferation of fibroblasts, increased collagen deposition and alteration of the extracellular matrix (ECM). These changes generate relaxation and diastolic dysfunction which reduced cardiac performance. The overactivity of the sympathetic nervous system plays an essential role in the development of hypertension and left ventricular hypertrophy pathogenesis due to the excessive release of catecholamines and norepinephrine spillover and their effects on the secretion of pro-inflammatory cytokines and hypertrophic signaling pathways. Antihypertensive treatment with moxonidine, a centrally acting sympatholytic imidazoline compound, results in prevention of left ventricular hypertrophy, resulting from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation that occur early after treatment. Due to the interaction between LVH, inflammatory cytokines, the SNS and their effects on hypertrophic signaling proteins, the objective of this study is to detect in an animal model of hypertension and LVH, the different signaling pathways associated with regression of LVH and cardiac performance. Spontaneously hypertensive rats (SHR, 12 weeks old) received moxonidine at 0, 100 and 400 µg/kg/h, for 1 and 4 weeks, via subcutaneously implanted osmotic minipumps. After 4 weeks of treatment, cardiac performance was measured by echo-Doppler. Then the rats were euthanized, blood was collected for measurement of plasma cytokines and hearts for histologic determination of collagen deposition and for measurement of left ventricular expression of downstream signaling proteins. Treatment for 4 weeks had no effect on systolic parameters but improved diastolic parameters and global cardiac performance. Compared to vehicle, moxonidine (400 µg/kg/h) transiently increased plasma IL-1β after 1 week and reduced left ventricular mass. Similarly, there was a decrease in collagen deposition and plasma concentrations of IL-6 and TNF-α, and decreased phosphorylation of p38 and Akt in the left ventricle after 1 and 4 weeks treatment, in association with reduced blood pressure and heart rate. Interestingly, the anti-hypertrophic, anti-fibrotic, and anti-inflammatory effects of moxonidine were observed with a sub-hypotensive dose (100µg/kg/h). These results suggest the beneficial cardiovascular effects of moxonidine associated with improved cardiac performance, regulation of inflammation by decreasing pro-inflammatory plasma levels, inhibition of p38 MAPK and Akt, and allow us to suggest that besides inhibiting the SNS, moxonidine may act on peripheral sites.
|
9 |
Envolvimento de receptores muscarínicos centrais no controle da ingestão de sódioAnesio, Augusto 10 July 2017 (has links)
Submitted by Aelson Maciera (aelsoncm@terra.com.br) on 2018-01-30T17:09:56Z
No. of bitstreams: 1
DissAA.pdf: 1196078 bytes, checksum: c96629c7fdc72285ebf9260f9394bbae (MD5) / Approved for entry into archive by Ronildo Prado (bco.producao.intelectual@gmail.com) on 2018-02-01T17:39:56Z (GMT) No. of bitstreams: 1
DissAA.pdf: 1196078 bytes, checksum: c96629c7fdc72285ebf9260f9394bbae (MD5) / Approved for entry into archive by Ronildo Prado (bco.producao.intelectual@gmail.com) on 2018-02-01T17:40:05Z (GMT) No. of bitstreams: 1
DissAA.pdf: 1196078 bytes, checksum: c96629c7fdc72285ebf9260f9394bbae (MD5) / Made available in DSpace on 2018-02-01T17:44:38Z (GMT). No. of bitstreams: 1
DissAA.pdf: 1196078 bytes, checksum: c96629c7fdc72285ebf9260f9394bbae (MD5)
Previous issue date: 2017-07-10 / Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Water and sodium intake are fundamental behaviors for body fluid homeostasis. These behaviors are controlled by a neural circuitry involving facilitatory and inhibitory mechanisms, which are modulated by signals activated by changes in body fluid volume and composition. Important inhibitory mechanisms for water intake and particularly for sodium intake are located in the lateral parabrachial nucleus (LPBN), a pontine structure. It is known that LPBN inhibitory mechanisms are controlled by several neurotransmitters, some increasing, others reducing the action of this nucleus on sodium intake... / A ingestão de água e a ingestão de sódio são comportamentos fundamentais para a homeostase dos líquidos corporais. A manifestação destes comportamentos é controlada por um circuito neural constituído por mecanismos facilitatórios e inibitórios os quais são constantemente modulados por informações relativas aos líquidos corporais. Importantes mecanismos inibitórios para a ingestão de água e especialmente para a ingestão de sódio localizam-se no núcleo parabraquial lateral (NPBL), uma estrutura pontina. Sabe-se que os mecanismos inibitórios do NPBL são controlados por diversos neurotransmissores, alguns aumentando e outros diminuindo a ação deste núcleo sobre a ingestão de sódio .....
|
10 |
Cardiac cell fate control by the imidazoline I1 receptor/nischarin : application in cardiac pathologyAceros Muñoz, Henry Adolfo 08 1900 (has links)
La moxonidine, un médicament antihypertenseur sympatholytique de type imidazolinique, agit au niveau de la médulla du tronc cérébral pour diminuer la pression artérielle, suite à l’activation sélective du récepteur aux imidazolines I1 (récepteur I1, aussi nommé nischarine). Traitement avec de la moxonidine prévient le développement de l’hypertrophie du ventricule gauche chez des rats hypertendus (SHR), associé à une diminution de la synthèse et une élévation transitoire de la fragmentation d’ADN, des effets antiprolifératifs et apoptotiques. Ces effets se présentent probablement chez les fibroblastes, car l’apoptose des cardiomyocytes pourrait détériorer la fonction cardiaque. Ces effets apparaissent aussi avec des doses non hypotensives de moxonidine, suggérant l’existence d’effets cardiaques directes. Le récepteur I1 se trouvé aussi dans les tissus cardiaques; son activation ex vivo par la moxonidine stimule la libération de l’ANP, ce qui montre que les récepteurs I1 cardiaques sont fonctionnels malgré l’absence de stimulation centrale.
Sur la base de ces informations, en plus du i) rôle des peptides natriurétiques comme inhibiteurs de l’apoptose cardiaque et ii) des études qui lient le récepteur I1 avec la maintenance de la matrix extracellulaire, on propose que, à part les effets sympatholytiques centrales, les récepteurs I1 cardiaques peuvent contrôler la croissance-mort cellulaire. L’activation du récepteur I1 peut retarder la progression des cardiopathies vers la défaillance cardiaque, en inhibant des signaux mal adaptatifs de prolifération et apoptose.
Des études ont été effectuées pour :
1. Explorer les effets in vivo sur la structure et la fonction cardiaque suite au traitement avec moxonidine chez le SHR et le hamster cardiomyopathique.
2. Définir les voies de signalisation impliquées dans les changements secondaires au traitement avec moxonidine, spécifiquement sur les marqueurs inflammatoires et les voies de signalisation régulant la croissance et la survie cellulaire (MAPK et Akt).
3. Explorer les effets in vitro de la surexpression et l’activation du récepteur I1 sur la survie cellulaire dans des cellules HEK293.
4. Rechercher la localisation, régulation et implication dans la croissance-mort cellulaire du récepteur I1 in vitro (cardiomyocytes et fibroblastes), en réponse aux stimuli associés au remodelage cardiaque : norépinephrine, cytokines (IL-1β, TNF-α) et oxydants (H2O2).
Nos études démontrent que la moxonidine, en doses hypotensives et non-hypotensives, améliore la structure et la performance cardiaque chez le SHR par des mécanismes impliquant l’inhibition des cytokines et des voies de signalisation p38 MAPK et Akt. Chez le hamster cardiomyopathique, la moxonidine améliore la fonction cardiaque, module la réponse inflammatoire/anti-inflammatoire et atténue la mort cellulaire et la fibrose cardiaque. Les cellules HEK293 surexprimant la nischarine survivent et prolifèrent plus en réponse à la moxonidine; cet effet est associé à l’inhibition des voies ERK, JNK et p38 MAPK. La surexpression de la nischarine protège aussi de la mort cellulaire induite par le TNF-α, l’IL-1β et le H2O2.
En outre, le récepteur I1 s’exprime dans les cardiomyocytes et fibroblastes, son activation inhibe la mort des cardiomyocytes et la prolifération des fibroblastes induite par la norépinephrine, par des effets différentiels sur les MAPK et l’Akt.
Dans des conditions inflammatoires, la moxonidine/récepteur aux imidazolines I1 protège les cardiomyocytes et facilite l’élimination des myofibroblastes par des effets contraires sur JNK, p38 MAPK et iNOS.
Ces études démontrent le potentiel du récepteur I1/nischarine comme cible anti-hypertrophique et anti-fibrose à niveau cardiaque. L’identification des mécanismes cardioprotecteurs de la nischarine peut amener au développement des traitements basés sur la surexpression de la nischarine chez des patients avec hypertrophie ventriculaire. Finalement, même si l’effet antihypertenseur des agonistes du récepteur I1 centraux est salutaire, le développement de nouveaux agonistes cardiosélectifs du récepteur I1 pourrait donner des bénéfices additionnels chez des patients non hypertendus. / Moxonidine, an antihypertensive sympatholytic imidazoline compound, reduces blood pressure by selective activation of non-adrenergic imidazoline I1-receptors (also known as nischarin) in brainstem medulla. Moxonidine prevents left ventricular hypertrophy development in hypertensive rats, associated with reduced cardiac DNA synthesis and early transient increase in DNA fragmentation. It is likely that the anti-proliferative and apoptotic effects occur in fibroblasts, as cardiomyocyte apoptosis may deteriorate cardiac function. The effects also occurred to sub-hypotensive doses, suggesting a blood-pressure-independent mechanism and pointing to a local cardiac action. Imidazoline I1-receptors have been identified in cardiac tissues, and their ex vivo activation by moxonidine stimulates ANP release, demonstrating that cardiac imidazoline I1-receptors are functional without the contribution of the central nervous system.
Based on the above studies and on i) the role of natriuretic peptides in inhibition of myocardial cell apoptosis and ii) studies linking imidazoline I1-receptors to the maintenance of the extracellular matrix and PC12 cell survival, we propose that apart from centrally-mediated sympatholytic function, imidazoline I1-receptors in the heart may control cell growth and death. Activation of imidazoline receptors may delay the progression of cardiac pathologies into heart failure by inhibition of maladaptive proliferative signalling and downstream apoptotic pathways.
In order to test this hypothesis studies were performed to:
1. Explore the in vivo effects of moxonidine on cardiac structure and function in SHR and cardiomyopathic hamsters.
2. Define the pathways involved in the observed changes following moxonidine treatment, specifically, on inflammatory markers and pathways involved in LVH and cardiac cell survival/death (MAPK and Akt).
3. Explore in vitro the effect of imidazoline I1-receptor activation by moxonidine, on cell survival by over-expressing nischarin in HEK293 cells, to circumvent the lack of specific imidazoline I1-receptor agonists and antagonists.
4. Investigate in vitro, imidazoline I1-receptor localization (cardiomyocytes and fibroblasts), regulation and implication in cell growth/death in response to cardiac remodelling-associated stimuli: norepinephrine, cytokines (IL-1β, TNF-α), and oxidants (H2O2).
The studies reveal that hypotensive and sub-hypotensive concentrations of moxonidine improve cardiac structure and performance in SHR by mechanisms that involve inhibition of cytokines, p38MAPK, and Akt signalling pathways. In cardiomyopathic hamsters moxonidine improves cardiac performance, in association with differential inflammatory/anti-inflammatory responses that culminate in attenuated cardiomyocyte death and fibrosis and altered collagen type expression. HEK293 cells, transfected with nischarin cDNA, show increased viability/proliferation in response to moxonidine. The overall survival response is associated with moxonidine’s inhibition of ERK, JNK, and p38MAPK. Nischarin also opposes the reduced cell viability in response to oxidative stimuli (TNF-α, IL-1β and H2O2), with differential responses to moxonidine. Furthermore, the imidazoline I1-receptor is expressed in cardiac fibroblasts and myocytes and its activation inhibits norepinephrine-induced cardiomyocyte death and fibroblast proliferation, through differential effects on MAPKs and Akt. Moxonidine/imidazoline I1-receptor protects cardiomyocytes and facilitates elimination of myofibroblasts in inflammatory conditions, through opposite effects on JNK, p38MAPK and iNOS activity.
These studies emphasize the potential importance of imidazoline I1-receptor/nischarin as an anti-hypertrophic and anti-fibrotic target. Identification of the cardio-protective mechanisms of cardiac nischarin could result in specifically-tailored cell/gene-driven nischarin treatments, which could be important for patients with heart disease. Also, while the antihypertensive action of centrally acting compounds is appreciated, new cardiac-selective I1-receptor agonists may confer additional benefit.
|
Page generated in 0.034 seconds